Trial Profile
An Open-label, Short-duration, Repeat-dose Study of Breastmilk Excretion and Infant Absorption of Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine When Used by HIV-uninfected Lactating Women
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 22 Sep 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- 31 May 2016 New trial record